|
|
 |
DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Authors
In compliance with standards established by ASCO’s Conflict of Interest Policy (J Clin Oncol 24:519, 2006), ASCO’s intent is to promote balance, independence, objectivity, and scientific rigor in all of its editorial policies related to JCO, through the disclosure of financial and other interests, and in the identification and management of potential conflicts. The financial interests or relationships requiring disclosure are outlined in the ASCO Conflict of Interest Policy. All contributors to JCO are required to disclose financial and other relationships with entities that have an investment, licensing, or other commercial interest in the subject matter of their manuscript. These disclosures should include, but are not limited to, relationships with pharmaceutical and biotechnology companies, device manufacturers, or other commercial entities whose products or services are related to the subject matter of the submission.
Disclosures of financial interests or relationships involving the authors must be addressed on the Author Disclosure Declaration. Each author must complete a declaration form for each manuscript submitted. The corresponding author must enter this information as part of the online submission process, but should not send hard copies of the forms to the Editorial Office. There are two versions of the Author Disclosure Declaration that can be downloaded here:
Author Disclosure Declaration and Author Contribution forms for submissions reporting on clinical trials
Author Disclosure Declaration and Author Contribution forms for submissions not reporting on clinical trials
The forms are also available for download in the Author Area of the manuscript processing system or upon request from the Editorial Office. The Editorial Office recommends that corresponding authors collect the Author Disclosure Declaration from all other authors before starting the formal online submission. All disclosures appear in print at the end of all published articles.
Disclosure of Research Funding Instructions
- Disclose financial research support received from commercial entities under question #5 (Research Funding) on the Author Disclosure Declaration (note that funding from government or nonprofit entities should not be disclosed here).
- Acknowledge financial research support of the study on the manuscript title page (see Manuscript Preparation Guidelines), rather than on the form.
- Disclose commercial research funding received by an author’s institution, cooperative group, or clinical division on the form if the author has received benefit (eg, salary support).
- For more information, see Questions and Answers Regarding the ASCO Conflict of Interest Policy.
Principal Investigator Restrictions
For reports based on clinical trials that began accrual on or after April 29, 2004, the ASCO Conflict of Interest Policy places some restrictions on the financial relationships of Principal Investigators (PIs). If a PI holds any relationships that are restricted by the Policy, his or her manuscript may require an exception to the ASCO Conflict of Interest Policy in order to be considered for publication. NIH funded trials are exempt from the Principal Investigator Restrictions. The principal investigator is the individual (or individuals) with primary responsibility for the development of the protocol, the conduct of the trial, and the interpretation and dissemination of the trial data. There may be more than one principal investigator in a multifaceted trial with separate and distinct subsections of the protocol, but lead investigators at individual sites in a multisite trial are not considered principal investigators for purposes of this policy.
For more information about applying for an exception to the PI Restrictions, please see the ASCO Conflict of Interest Policy (J Clin Oncol 24:519, 2006) and Exception Request Materials. Applying for an exception requires the submission of additional materials. These materials can be uploaded into the BenchPress system during the submission process at http://submit.jco.org or emailed directly to coi{at}asco.org.
Editors and Reviewers
Editors and reviewers are required to disclose financial interests or relationships, and are asked to answer the same questions as authors. Reviewers are asked to disclose potential conflicts when accepting a review assignment. These disclosures are held in confidence within the Editorial Office, while the Editors’ disclosures are published online annually as an adjunct to "JCO and the Public Trust" (J Clin Oncol 24:323, 2004). To find the Editors’ disclosure information, click on the Editors’ Disclosure Statement link associated with this article.
If in doubt about reporting any potential conflict of interest, it is better to declare a conflict than not. For additional information regarding ASCO’s Conflict of Interest Policy, see this Web site.
|
